Dr. Christopher David Vercammen-Grandjean, MD

Dr. Vercammen-Grandjean practices at J M Geiss DO APC in Orange, California.

Dr. Vercammen-Grandjean's NPI, 1942543699, was assigned on April 1, 2013. Dr. Vercammen-Grandjean graduated from UCSF School of Medicine in 2013. Dr. Vercammen-Grandjean holds California license A135720.

Dr. Vercammen-Grandjean's primary practice is J M Geiss DO APC, at 2592 N Santiago Blvd, Orange, CA 92867 in Orange County. The practice phone is (855) 434-7763.

Dr. Vercammen-Grandjean's primary practice is J M Geiss DO APC in Orange, California. The medical group on file is PIH Health Physicians (John M. Geiss, DO). Dmand AI also links Dr. Vercammen-Grandjean to 6 more medical groups, 5 group practices and clinics and 2 home health agencies, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Vercammen-Grandjean practices, 7 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Vercammen-Grandjean's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Vercammen-Grandjean is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Vercammen-Grandjean's licenses on file in 7 states: California, Florida, Nevada, New York, Ohio, North Carolina and Washington.

Dmand AI lists acid reflux, acute skin infection, alzheimer's disease, anxiety, aortic atherosclerois, arthritis, atrial fibrillation and flutter and chronic diabetes among the conditions Dr. Vercammen-Grandjean treats.

CMS data shows 472 Medicare services from Dr. Vercammen-Grandjean across 8 procedure codes in 2024, for 182 Medicare patients. Medicare paid $34,966 for them. Every service was in an office.

CMS counts 182 Medicare patients who saw Dr. Vercammen-Grandjean in 2024. The largest group is 65 to 74, with 97 patients. 71% of them have high blood pressure, and 68% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.22, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Vercammen-Grandjean's median patient age at 76, with 51% women.

In 2024, Dr. Vercammen-Grandjean wrote 8,130 Medicare Part D claims for 647 patients. 87% of them were for generic drugs. CMS names the drug for 7,276 of them, across 154 drugs with 11 or more claims each, at $682,171 in total drug cost. In 2023, CMS named 6,488 claims across 144 drugs.

Dr. Vercammen-Grandjean accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 3 papers to Dr. Vercammen-Grandjean, published from 2011 to 2018. Dr. Vercammen-Grandjean's most frequent co-authors are Michelle Sarah Mourad, MD, Edgar Pierluissi, MD and Katie E. Raffel, MD.

CMS Open Payments shows 6 general payments to Dr. Vercammen-Grandjean from 4 drug and device companies from 2018 to 2023. Education make up the largest share, 57% of the total. Abbott Laboratories paid the most, $265.

Dr. Vercammen-Grandjean graduated from UCSF School of Medicine in 2013. Dr. Vercammen-Grandjean is a member of ACP.

Dr. Vercammen-Grandjean is in network with 6 carriers, including Elevance, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.